Valuation: PFIZER

Market Cap 143B 143B 125B 116B 107B 201B 13,804B 204B 1,393B 543B 6,733B 535B 524B 23,359B P/E 2026 *
12.7x
P/E 2027 * 13.2x
Enterprise Value 192B 192B 169B 157B 144B 270B 18,578B 275B 1,874B 731B 9,062B 720B 705B 31,438B EV / Sales 2026 *
3.11x
EV / Sales 2027 * 3.13x
Free-Float
59.06%
Yield 2026 *
6.9%
Yield 2027 * 6.97%
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 60 02/05/2022
Chief Tech/Sci/R&D Officer - 01/01/2007
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%+1.43%+48.44%+156.66% 1,057B
+1.42%+3.72%+53.32%+52.34% 624B
+1.43%+0.99%+34.83%+78.74% 454B
+0.50%+5.00%+32.37%+28.30% 341B
-0.89%+1.18%+35.23%+39.30% 297B
-0.63%+0.04%+15.52%+16.87% 262B
-0.76%-3.62%-28.88%-42.19% 215B
+1.49%-0.02%+20.14%+58.21% 201B
+0.40%-3.99%+15.23%+62.28% 162B
Average +0.56%+0.77%+25.13%+50.06% 401.55B
Weighted average by Cap. +0.99%+1.57%+34.91%+75.41%

Financials

2026 *2027 *
Net sales 61.77B 61.77B 54.32B 50.47B 46.41B 87.04B 5,982B 88.6B 603B 235B 2,918B 232B 227B 10,122B 59.37B 59.37B 52.22B 48.51B 44.62B 83.67B 5,750B 85.17B 580B 226B 2,804B 223B 218B 9,729B
Net income 10.63B 10.63B 9.35B 8.68B 7.99B 14.98B 1,029B 15.24B 104B 40.5B 502B 39.9B 39.03B 1,741B 10.27B 10.27B 9.03B 8.39B 7.72B 14.47B 994B 14.73B 100B 39.13B 485B 38.55B 37.71B 1,683B
Net Debt 49.3B 49.3B 43.36B 40.28B 37.05B 69.47B 4,774B 70.72B 482B 188B 2,329B 185B 181B 8,079B 43.17B 43.17B 37.97B 35.27B 32.44B 60.83B 4,180B 61.92B 422B 165B 2,039B 162B 159B 7,074B
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (42.9%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (28%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (26.9%); - other (2.2%). The United States accounts for 59.2% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A